Charts

According to data from Benzinga Pro, during Q4, Syros Pharmaceuticals's (NASDAQ:SYRS) reported sales totaled $-754 thousand. Despite a ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2022 Earnings Call Transcript March 2, 2023 Operator: Good morning, and welcome to Syros Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Syros’ website […]

Syros Pharmaceuticals ( NASDAQ:SYRS ) Full Year 2022 Results Key Financial Results Revenue: US$14.9m (down 37% from FY...

Credit Suisse cut the price target for Hormel Foods Corporation (NYSE: HRL) from $44 to $41. Credit Suisse analyst Robert Moskow ...

Q4 2022 Syros Pharmaceuticals Inc Earnings Call

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter and full-year ended December 31, 2022 and provided a corporate update.

Syros Pharmaceuticals (NASDAQ:SYRS) is set to give its latest quarterly earnings report on Thursday, 2023-03-02. Here's what investors ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a panel discussion and present a corporate overview at two upcoming investor conferences in March. Management will also be available for one-on-one meetings. Details are as follows:

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 12,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Syros Pharmaceuticals, Inc. (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Gainers Akanda (NASDAQ:AKAN) stock increased by 28.2% to $0.36 during Thursday's after-market session. Akanda's trading volume hit 4.1 ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to tamibarotene for the treatment of higher-risk myelodysplastic syndrome (HR-MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overexpression.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in advancing new standards of care for the frontline treatment of hematologic malignancies, today provided an update on its clinical development programs and outlined its strategic priorities for 2023.

Syros Pharmaceuticals (NASDAQ:SYRS) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

On Tuesday, 298 companies achieved new lows for the year. Areas of Interest About Today's 52-Week ...

On Monday, 297 companies reached new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest ...

Viewing insider transactions for Syros Pharmaceuticals, Inc.'s ( NASDAQ:SYRS ) over the last year, we see that insiders...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy. These findings support Syros’ ongoing evaluation of tamibarotene for the treatment of AML and myelodysplastic syndrome (MDS) patients with RARA overexpression. The paper, titled “Targeting RARA Overexpression with Tamibarotene, a Potent and Selective RARα Agonist, is a Novel Approach in AML,” was published online in Blood Advances on December 7, 2022 at https://doi.org/10.1182/bloodadvances.2022008806.

CAMBRIDGE, Mass., December 12, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy. These findings support Syros’ ongoing evaluation of tamibarotene for the

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression. The data is being presented today in a poster session at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, LA.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a virtual event to discuss initial data from the safety lead-in portion of the ongoing Phase 2 SELECT-AML-1 clinical trial and to review the unmet need in newly diagnosed, unfit acute myeloid leukemia (AML). The event will be held on Saturday, December 10, 2022 beginning at 12:00 p.m. ET.

Gainers Tenaya Therapeutics (NASDAQ:TNYA) shares moved upwards by 11.4% to $2.72 during Wednesday's after-market session. The market ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. Management will also be available for one-on-one meetings. Details are as follows:

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present initial data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 clinical trial at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, LA. The SELECT-AML-1 trial is evaluating tamibarotene, Syros’ first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA gene overexpression.

Gainers NextPlay Technologies, Inc. (NASDAQ: NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company ...

Thursday saw 177 companies set new 52-week lows. 52-Week Low Highlights: Tesla (NASDAQ:TSLA) was the largest firm by ...

Syros Pharmaceuticals's (NASDAQ:SYRS) short percent of float has fallen 48.18% since its last report. The company recently reported ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors are still interested in short squeeze stocks lately and we've got them covered with the ones to watch this week! The post GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge ...

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) rose 58.2% to $8.70 in pre-market trading. BYND Cannasoft shares jumped ...

Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday. Purple Innovation, Inc. ...

Stocks are struggling for direction midday. The Dow Jones Industrial Average was last seen slightly below breakeven, while the S&P 500 Index and the Nasdaq Composite are back in the red.

Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74. BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) ...

Syros Pharmaceuticals's (NASDAQ:SYRS) short percent of float has risen 5.3% since its last report. The company recently reported that it ...

U.S. stocks traded lower this morning, after recording losses in the previous week. Following the market opening Monday, the Dow ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Shares of the combined company will trade on Nasdaq under the ticker symbol “SYRS.”

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Kensington Capital Acquisition Corp. IV (NYSE: AMPX) rose 159.4% to $25.94 in pre-market trading after gaining 11% on ...

Pre-open movers U.S. stock futures traded lower in early pre-market trade on Friday after recording losses on Thursday. The Nasdaq ...

With US stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 2022. At TYME’s special meeting, TYME’s stockholders voted in favor of all proposals, including the proposal to adopt the agreement and plan of merger, dated July 3, 2022 (the “Merger Agreement”), pursuant to which a direct, wholly owned subsidiary of Syros will merge with and into TYME, with TYME surviving as a wholly owned subsidiary of Syros (the “Merger”). At Syros’ special meeting, Syros’ stockholders also voted in favor of all proposals, including the proposal to approve the issuance of shares of Syros’ common stock to holders of TYME’s common stock in connection with the Merger and to certain of Syros’ investors in connection with a concurrent private investment in public equity (“PIPE”) financing.

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase ...

Akero Therapeutics (NASDAQ: AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate ...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SY-5609 for the treatment of pancreatic cancer. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for the treatment of patients with relapsed metastatic pancreatic cancer.